bioMérieux, a world leader in the field of in vitro diagnostics, announces the CE marking of its innovative and fully-automated assays to diagnose dengue infection: VIDAS® DENGUE NS1 Ag VIDAS® Anti-DENGUE IgM VIDAS® Anti-DENGUE IgG
bioMérieux announces the CE marking of TB IGRA® test on VIDAS®
24 Marzo, 2021
Today marks World Tuberculosis (TB) Day and bioMérieux, a world leader in the field of in vitro diagnostics, announces the CE marking of its innovative and fully-automated test VIDAS® TB IGRA (Interferon-Gamma Release Assay) to diagnose latent TB infection.
BIOFIRE® Respiratory 2.1 (RP2.1) Panel with SARS-CoV-2 obtains De Novo FDA Authorization
18 Marzo, 2021
Marcy l’Étoile (France) – bioMérieux, a world leader in the field of in vitro diagnostics, today announced that BioFire Diagnostics, its subsidiary specialized in molecular syndromic infectious disease testing, has received U.S. Food and Drug Administration (FDA) De Novo authorization for the BIOFIRE® RP2.1 Panel.
bioMérieux – 2020 Financial Results
24 Febbraio, 2021
bioMérieux annuncia la marcatura CE del test NEPHROCHECK® su VIDAS®
03 Febbraio, 2021
Marcy l’Etoile, Francia – 3 Febbraio, 2021 – bioMérieux, leader globale nella diagnostica in vitro comunica la marcatura CE dell’innovativo test NEPHROCHECK® in grado di individuare lo stress renale nei pazienti a rischio di danno renale acuto (AKI).
bioMérieux announces the expansion of the CE marking of its molecular biology ARGENE® SARS-CoV-2 diagnostic test to include saliva specimens.
17 Novembre, 2020
Marcy l’Etoile, France – November 16, 2020 – bioMérieux, a world leader in the field of in vitro diagnostics, has announced the expansion of its ARGENE® range for the detection of SARS-CoV-2. As a complement to nasopharyngeal swab specimens, the singleplex SARS-CoV-2 R-GENE® real-time PCR test may now be used on saliva and oropharyngeal (throat) swab specimens for the detection of the virus that causes COVID-19. This development helps optimize laboratory workflows.
First-Half 2020 Results
02 Settembre, 2020
BIOFIRE® Respiratory Panel 2.1 plus with SARS-CoV-2 is CE marked
15 Luglio, 2020